Oct 8, 2026
What pCR rates can be achieved with neoadjuvant THP, and which patients are most likely to respond? Host Dr. Davide Soldato interviews Dr. Nadine Tung on her article, “Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary...
Sep 28, 2026
Host Dr. Jake New interviews Dr. Makoto Tahara about the JCO article "Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer." They discuss clinical considerations for individualizing treatment...
Sep 10, 2026
How does dexrazoxane affect left ventricular function over time after doxorubicin treatment for childhood cancer? Host Dr. Davide Soldato sits down with Dr. Erin Mobley and Dr. Eric Chow to discuss their article, “Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report from...
Aug 13, 2026
Guest Dr. Vedang Murthy and host Davide Soldato discuss JCO article, "Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer" and delve into trial design, results, clinical implications, and future...
Jul 27, 2026
In this episode of JCO Article Insights, host Ash Gurumurthi summarizes the article "Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma," by Mehta-Shah and colleagues.